Active Clinical Trials

Active Thyroid Cancer Specific Trials

For available solid tumor basket trials please e-mail us at scthycc@labiomed.org or call 310-222-8172.

1) A Phase 3 Trial Comparing Loxo-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)- Link to come soon.

2)  Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

3) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

4) A Study of Cabozantinib Compared with Placebo in Subjects with Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

5) Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-positive Solid Tumors, and Medullary Thyroid Cancer

6) Phase I Study of BLU-667 (highly selective RET inhibitor) for MTC and PTC

7) Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer

8) Phase II Clinical Trial for Tipifarnib for HRAS-mutant Thyroid Cancer

9) Active Surveillance of Papillary Thyroid Microcarcinoma